Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Users Online: 494 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others

BRIEF COMMUNICATION

Obinutuzumab: A FDA approved monoclonal antibody in the treatment of untreated chronic lymphocytic leukemia

Sachdeva Mamta, Dhingra Sameer

Year : 2015| Volume: 5| Issue : 1 | Page no: 54-57

   This article has been cited by
 
1 Targeted selective degradation of Bruton’s tyrosine kinase by PROTACs
Shaodong Liu,Yang Da,Feng Wang,Renjie Yan,Yongzhi Shu,Pei Lin,Jun Lin
Medicinal Chemistry Research. 2020;
[Pubmed]  [Google Scholar] [DOI]
2 The development of Brutonæs tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review
Chengyuan Liang,Danni Tian,Xiaodong Ren,Shunjun Ding,Minyi Jia,Minhang Xin,Suresh Thareja
European Journal of Medicinal Chemistry. 2018;
[Pubmed]  [Google Scholar] [DOI]
3 Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy
Juan C. Almagro,Tracy R. Daniels-Wells,Sonia Mayra Perez-Tapia,Manuel L. Penichet
Frontiers in Immunology. 2018; 8
[Pubmed]  [Google Scholar] [DOI]
4 Unexpected cross-reactivity of anti-cathepsin B antibodies leads to uncertainties regarding the mechanism of action of anti-CD20 monoclonal antibody GA101
Wei Wen Chien,Charlène Niogret,Romain Jugé,Loïc Lionnard,Aurélie Cornut-Thibaut,Jérôme Kucharczak,Ariel Savina,Gilles Salles,Abdel Aouacheria
Leukemia Research. 2017; 55: 41
[Pubmed]  [Google Scholar] [DOI]
5 Hepatotoxicity of targeted therapy for cancer
Kirsty Wai-Chung Lee,Stephen Lam Chan
Expert Opinion on Drug Metabolism & Toxicology. 2016; 12(7): 789
[Pubmed]  [Google Scholar] [DOI]
6 The state-of-play and future of antibody therapeutics
Zehra Elgundi,Mouhamad Reslan,Esteban Cruz,Vicki Sifniotis,Veysel Kayser
Advanced Drug Delivery Reviews. 2016;
[Pubmed]  [Google Scholar] [DOI]

 

Read this article